Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Rodríguez-Agirretxe, Iñaki; Freire, Vanesa; Muruzábal, Francisco; Orive, Gorka; Anitua, Eduardo; Díez-Feijóo, Elio; Acera, Arantxa

doi:10.1159/000481535

Cited by 14 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5 conditions include: injecting E-PRP into anterior chamber to treat keratoconus hydrops (one case), 50 intracameral E-PRP injection to treat ocular hypotension post glaucoma surgery (one case), 51 using PRP from blood bank to mix with other materials to form a moldable paste to reconstruct orbital floor fracture (10 cases), 52 injecting autologous PRP to treat retinitis pigmentosa (37 patients), 53 and using PRGF fibrin membrane to treat medically uncontrolled primary open angel glaucoma (n=10). 54 All these studies reported positive outcomes with significant improvement in clinical signs and symptoms.…”

Section: Resultsmentioning

confidence: 99%

“…Significant improvement in visual field, multifocal electroretinography and microperimetry values at follow-up. Rodriguez-Agirretxe et al 2018 54 Prospective, non-randomized, non-comparative, interventional case series (Level IV) Primary open angle glaucoma 10 No mPRGF Single application 24 months Statistically significant reduction in IOP Ocular surface regeneration following glaucoma surgery. Abdalrahman et al 2019 51 Case report (Level VI) Ocular hypotension post glaucoma surgery non-responsive to treatment 1 No E-PRP injection Single injection 6 months Improved intraocular pressure Stable clinical signs at final follow up Alio et al 2019 50 Case report (Level VI) Keratoconus hydrops 1 No Autologous E-PRP injection Single injection 6 months Clinical signs resolved by 1 week Stability through 6 months.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review

You¹,

Hodge²,

Hoque³

et al. 2020

OPTH

View full text Add to dashboard Cite

Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review

You¹,

Hodge²,

Hoque³

et al. 2020

OPTH

View full text Add to dashboard Cite

show abstract

“…The IOP also showed a significant improvement (p < 0.027), results similar to those obtained in other PRGF related studies, 8,10,25 being some of these directly or indirectly related to glaucoma. 27 Further studies may be beneficial to clarify the role of PRGF for the management of the IOP and its clinical applications.…”

Section: Discussionmentioning

confidence: 99%

Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis

Montero-Iruzubieta¹,

Sánchez-Ávila

Orive

et al. 2020

OPTH

Self Cite

View full text Add to dashboard Cite

The objective was to evaluate the clinical results obtained from the use of immunosafe plasma rich in growth factors (isPRGF) in the treatment of patients with cicatrizing conjunctivitis (CC) who had not responded to the usual therapy. Patients and Methods: This is a retrospective study that included patients diagnosed with CC, in whom isPRGF was used in different phases (I: eye drops; II: eye drops and injectable; III: eye drops, injectable and surgical treatment) to achieve control of the inflammation. As a clinical follow-up of the patients, the better corrected visual acuity (BCVA), degree of inflammation (measured from 1 to 4), the severity of the CC, Schirmer I test, IOP and TBUT were analyzed. The adverse events were also evaluated. Results: Ten eyes (6 patients) were evaluated, 50% corresponded to Stevens-Johnson Syndrome and 50% to ocular mucous membrane pemphigoid. The mean age was 59.7 ± 16.5 (39-80) years, and 50% were women. Fifty per cent of the cases were initially considered severe CC, and 10% of the cases (one eye of one patient) were considered severe CC at the end of the treatment (p = 0.046). The initial degree of inflammation was 2 in 4 eyes, 3 in two eyes, and 4 in 4 eyes, and final inflammation degree was 1 in all cases (p = 0.004). Twenty per cent of the cases achieved stability in Phase I of the treatment with immunosafe PRGF, 70% with both Phases I and II, and only one case underwent Phase III to achieve stability. The IOP improved significantly (p = 0.027) though the BCVA, TBUT and Schirmer I test showed no significant changes. The follow-up time was 23.1 ± 6.7 (13.6-30.3) months. No adverse effects were reported. Conclusion: Treatment with PRGF technology in its injectable and topical immunosafe formulations may be a novel alternative for the treatment of patients with CC, given its complement activity modulating effect, as well as its anti-inflammatory, antifibrotic and regenerative properties.

show abstract

“…The biological properties of PRGF would theoretically be of great help in reducing fibrosis after NPDS. Rodriguez-Agirretxe et al [12], in a pilot study, evaluated a case series of 10 eyes that underwent NPDS with a PRGF clot inserted in the subconjunctival space. The authors concluded that PRGF might enhance surgery success rates and reduce the need for postoperative medications.…”

Section: Introductionmentioning

confidence: 99%

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Rodríguez-Calvo

Rodríguez-Uña

Fernández-Vega-Cueto

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Background: The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS). Methods: This is a case–control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops. Results: Preoperatively, group one (n = 48 eyes) and group two (n = 47 eyes) were similar in age (71.5 ± 10.7 vs. 70.9 ± 10.0 years; p = 0.68), IOP (20.6 ± 10.2 vs. 23.0 ± 9.0 mmHg; p = 0.26) and number of hypotensive drugs (2.7 ± 0.8 vs. 2.8 ± 0.9; p = 0.40). The IOP at six months dropped to 15.0 ± 8.0 mmHg (IOP reduction: −27.2%) and 10.9 ± 4.3 mmHg (IOP reduction: −52.6%) for group one and group two, respectively (p < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two (p = 0.06). No specific complications related to the use of is-ePRGF were identified. Conclusions: Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.

show abstract

Subconjunctival PRGF Fibrin Membrane as an Adjuvant to Nonpenetrating Deep Sclerectomy: A 2-Year Pilot Study

Cited by 14 publications

References 44 publications

<p>Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review</p>

<p>Human Platelets and Derived Products in Treating Ocular Surface Diseases – A Systematic Review</p>

<p>Plasma Rich in Growth Factors for the Treatment of Cicatrizing Conjunctivitis</p>

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Contact Info

Product

Resources

About